AU-rich RNA binding proteins in hematopoiesis and leukemogenesis

Blood

Volumn 118, Issue 22, 2011, Pages 5732-5740

  Baou, Maria ^a   Norton, John D ^a   Murphy, John J ^b  

^a UNIVERSITY OF ESSEX   (United Kingdom)

^b UNIVERSITY OF WESTMINSTER   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

CYTOKINE; HETEROGENEOUS NUCLEAR RIBONUCLEOPROTEIN D; HUR PROTEIN; KSRP PROTEIN; MESSENGER RNA; NUCLEOLIN; PEPTIDES AND PROTEINS; RNA BINDING PROTEIN; TRANSCRIPTOME; TRISTETRAPROLIN; TUMOR SUPPRESSOR PROTEIN; UNCLASSIFIED DRUG;

3' UNTRANSLATED REGION; CELL GROWTH; CELL SURVIVAL; GENE REGULATORY NETWORK; HEMATOPOIESIS; LEUKEMIA; LEUKEMOGENESIS; LYMPHOMA; PATHOPHYSIOLOGY; PRIORITY JOURNAL; PROTEIN ANALYSIS; PROTEIN DEGRADATION; PROTEIN EXPRESSION; PROTEIN FUNCTION; PROTEIN PROCESSING; REVIEW;

EID: 82155183375     PISSN: 00064971     EISSN: 15280020     Source Type: Journal    
DOI: 10.1182/blood-2011-07-347237     Document Type: Review

References (103)

1. Vogel C, Abreu RS, Ko D, et al. Sequence signatures and mRNA concentration can explain two-thirds of protein abundance variation in a human cell line. Mol Syst Biol. 2010;6:400.
2. Glisovic T, Bachorik J, Yong J, Dreyfuss G. RNA-binding proteins and post-transcriptional gene regulation. FEBS Lett. 2008;582(14):1977-1986.
3. Stumpo DJ, Lai WS, Blackshear PJ. Inflammation: cytokines and RNA-based regulation. WIREs RNA. 2010;1:60-80.
4. Gruber AR, Fallmann J, Kratochvill F, Kovarik P, Hofacker IL. AREsite: a database for the comprehensive investigation of AU-rich elements. Nucleic Acids Res. 2011;39(database issue):D66-D69.
5. Baou M, Jewell A, Murphy J. TIS11 family proteins and their roles in posttranscriptional gene regulation. J Biomed Biotechnol. 2009;2009:634520.
6. Khabar KS. Post-transcriptional control during chronic inflammation and cancer: a focus on AU-rich elements. Cell Mol Life Sci. 2010;67(17):2937-2955.
7. Anderson P. Post-transcriptional regulons coordinate the initiation and resolution of inflammation. Nat Rev Immunol. 2010;10(1):24-35.
8. von Roretz C, Gallouzi IE. Decoding ARE-mediated decay: is microRNA part of the equation? J Cell Biol. 2008;181(2):189-194.
9. Mazan-Mamczarz K, Hagner P, Dai B, Corl S, Liu Z, Gartenhaus R. Targeted suppression of MCT-1 attenuates the malignant phenotype through a translational mechanism. Leuk Res. 2009;33(3):474-482.
10. Liao B, Hu Y, Brewer G. Competitive binding of AUF1 and TIAR to MYC mRNA controls its translation. Nat Struct Mol Biol. 2007;14(8):511-518. (Pubitemid 46871812)
11. Wilson G, Lu J, Sutphen K, et al. Phosphorylation of p40(AUF1) regulates binding to A+U-rich mRNA-destabilizing elements and protein-induced changes in ribonucleoprotein structure. J Biol Chem. 2003;278(35):33039-33048. (Pubitemid 37055749)
12. Lapucci A, Donnini M, Papucci L, et al. AUF1 Is a bcl-2 A + U-rich element-binding protein involved in bcl-2 mRNA destabilization during apoptosis. J Biol Chem. 2002;277(18):16139-16146. (Pubitemid 34967900)
13. Palanisamy V, Park N, Wang J, Wong D. AUF1 and HuR proteins stabilize interleukin-8 mRNA in human saliva. J Dent Res. 2008;87(8):772-776.
14. Gouble A, Grazide S, Meggetto F, Mercier P, Delsol G, Morello D. A new player in oncogenesis: AUF1/hnRNPD overexpression leads to tumorigenesis in transgenic mice. Cancer Res. 2002;62(5):1489-1495. (Pubitemid 34407812)
15. Brewer G. An A + U-rich element RNA-binding factor regulates c-myc mRNA stability in vitro. Mol Cell Biol. 1991;11(5):2460-2466. (Pubitemid 21895624)
16. Bulfone-Paus S, Dempsey LA, Maizels N. Host factors LR1 and Sp1 regulate the Fp promoter of Epstein-Barr virus. Proc Natl Acad Sci U S A. 1995;92(18):8293-8297.
17. Brys A, Maizels N. LR1 regulates c-myc transcription in B-cell lymphomas. Proc Natl Acad Sci U S A. 1994;91(11):4915-4919. (Pubitemid 24177761)
18. Hanakahi L, Maizels N. Transcriptional activation by LR1 at the E mu enhancer and switch region sites. Nucleic Acids Res. 2000;28(14):2651-2657. (Pubitemid 30488007)
19. Tolnay M, Lambris J, Tsokos G. Transcriptional regulation of the complement receptor 2 gene: role of a heterogeneous nuclear ribonucleoprotein. J Immunol. 1997;159(11):5492-5501. (Pubitemid 127470077)
20. Sadri N, Lu JY, Badura ML, Schneider RJ. AUF1 is involved in splenic follicular B cell maintenance. BMC Immunol. 2010;11:1.
21. Fawal M, Armstrong F, Ollier S, et al. A "liaison dangereuse" between AUF1/hnRNPD and the oncogenic tyrosine kinase NPM-ALK. Blood. 2006;108(8):2780-2788.
22. Mathas S, Hinz M, Anagnostopoulos I, et al. Aberrantly expressed c-Jun and JunB are a hallmark of Hodgkin lymphoma cells, stimulate proliferation and synergize with NF-kappa B. EMBO J. 2002;21(15):4104-4113. (Pubitemid 34857442)
23. Donahue JM, Chang ET, Xiao L, et al. The RNA binding protein HuR stabilizes survivin mRNA in human esophageal epithelial cells. Biochem J. 2011;437(1):89-96.
24. Licata L, Hostetter C, Crismale J, Sheth A, Keen J. The RNA-binding protein HuR regulates GATA3 mRNA stability in human breast cancer cell lines. Breast Cancer Res Treat. 2010;122(1):55-63.
25. Drury G, Di Marco S, Dormoy-Raclet V, Desbarats J, Gallouzi I. FasL expression in activated T lymphocytes involves HuR-mediated stabilization. J Biol Chem. 2010;285(41):31130-31138.
26. Ishimaru D, Ramalingam S, Sengupta T, et al. Regulation of Bcl-2 expression by HuR in HL60 leukemia cells and A431 carcinoma cells. Mol Cancer Res. 2009;7(8):1354-1366.
27. Papadaki O, Milatos S, Grammenoudi S, Mukherjee N, Keene JD, Kontoyiannis DL. Control of thymic T cell maturation, deletion and egress by the RNA-binding protein HuR. J Immunol. 2009;182(11):6779-6788.
28. Moulton V, Kyttaris V, Juang Y, Chowdhury B, Tsokos G. The RNA-stabilizing protein HuR regulates the expression of zeta chain of the human T cell receptor-associated CD3 complex. J Biol Chem. 2008;283(29):20037-20044.
29. Abdelmohsen K, Lal A, Kim H, Gorospe M. Post-transcriptional orchestration of an anti-apoptotic program by HuR. Cell Cycle. 2007;6(11):1288-1292. (Pubitemid 47327958)
30. Yarovinsky T, Butler N, Monick M, Hunninghake G. Early exposure to IL-4 stabilizes IL-4 mRNA in CD4(+) T cells via RNA-binding protein HuR. J Immunol. 2006;177(7):4426-4435. (Pubitemid 44469771)
31. Durie D, Lewis SM, Liwak U, Kisilewicz M, Gorospe M, Holcik M. RNA-binding protein HuR mediates cytoprotection through stimulation of XIAP translation. Oncogene. 2011;30(12):1460-1469.
32. Kim H, Kuwano Y, Srikantan S, Lee E, Martindale J, Gorospe M. HuR recruits let-7/RISC to repress c-Myc expression. Genes Dev. 2009;23(15):1743- 1748.
33. Pillai R, Bhattacharyya S, Artus C, et al. Inhibition of translational initiation by Let-7 microRNA in human cells. Science. 2005;309(5740):1573-1576. (Pubitemid 41266485)
34. Xu F, Zhang X, Lei Y, et al. Loss of repression of HuR translation by miR-16 may be responsible for the elevation of HuR in human breast carcinoma. J Cell Biochem. 2010;111(3):727-734.
35. Guo X, Wu Y, Hartley RS. MicroRNA-125a represses cell growth by targeting HuR in breast cancer. RNA Biol. 2009;6(5):575-583.
36. Abdelmohsen K, Kuwano Y, Kim H, Gorospe M. Posttranscriptional gene regulation by RNA-binding proteins during oxidative stress: implications for cellular senescence. Biol Chem. 2008;389(3):243-255. (Pubitemid 351329020)
37. Kojima K, Fujita Y, Nozawa Y, Deguchi T, Ito M. MiR-34a attenuates paclitaxel-resistance of hormone-refractory prostate cancer PC3 cells through direct and indirect mechanisms. Prostate. 2010;70(14):1501-1512.
38. Lebedeva S, Jens M, Theil K, et al. Transcriptome-wide analysis of regulatory interactions of the RNA-binding protein HuR. Mol Cell. 2011;43:340-352.
39. Mukherjee N, Corcoran DL, Nusbaum JD, et al. Integrative regulatory mapping indicates that the RNA-binding protein HuR couples pre-mRNA processing and mRNA stability. Mol Cell. 2011;43:327-339.
40. Ghosh M, Aguila HL, Michaud J, et al. Essential role of the RNA-binding protein HuR in progenitor cell survival in mice. J Clin Invest. 2009;119(12):3530-3543.
41. Diaz-Munoz M, Fairfax K, Bell S, et al. Posttranscriptional mRNA regulation by the RNA binding protein HuR is critical for germinal center formation. Immunology. 2010;131(suppl 1):47.
42. Bergalet J, Fawal M, Lopez C, et al. HuR-mediated control of CEBPβ mRNA stability and translation in ALK-positive anaplastic large cell lymphoma. Mol Cancer Res. 2011;9(4):485-496.
43. Piva R, Pellegrino E, Mattioli M, et al. Functional validation of the anaplastic lymphoma kinase signature identifies CEBPB and BCL2A1 as critical target genes. J Clin Invest. 2006;116(12):3171-3182. (Pubitemid 44878631)
44. Topisirovic I, Siddiqui N, Orolicki S, et al. Stability of eukaryotic translation initiation factor 4E mRNA is regulated by HuR, and this activity is dysregulated in cancer. Mol Cell Biol. 2009;29(5):1152-1162.
45. Radich JP, Dai H, Mao M, et al. Gene expression changes associated with progression and response in chronic myeloid leukemia. Proc Natl Acad Sci U S A. 2006;103(8):2794-2799.
46. Calin GA, Cimmino A, Fabbri M, et al. MiR-15a and miR-16-1 cluster functions in human leukemia. Proc Natl Acad Sci U S A. 2008;105(13):5166-5171. (Pubitemid 351738528)
47. Abdelmohsen K, Kuwano Y, Kim HH, Gorospe M. Posttranscriptional regulation by RNA-binding proteins during oxidative stress: implications for cellular senescence. Biol Chem. 2008;289(3):243-245.
48. Mazan-Mamczarz K, Hagner P, Zhang Y, et al. ATM regulates a DNA damage response posttranscriptional RNA operon in lymphocytes. Blood. 2011;117(8):2441-2450.
49. Winzen R, Thakur BK, Dittrich-Breiholz O, et al. Functional analysis of KSRP interaction with the AU-rich element of interleukin-8 and identification of inflammatory mRNA targets. Mol Cell Biol. 2007;27(23):8388-8400. (Pubitemid 350234249)
50. Zhang X, Wan G, Berger FG, He X, Lu X. The ATM kinase induces microRNA biogenesis in the DNA damage response. Mol Cell. 2011;41(4):371-383.
51. Trabucchi M, Briata P, Garcia-Mayoral M, et al. The RNA-binding protein KSRP promotes the biogenesis of a subset of microRNAs. Nature. 2009;459(7249):1010-1014.
52. Ruggiero T, Trabucchi M, De Santa F, et al. LPS induces KH-type splicing regulatory protein-dependent processing of microRNA-155 precursors in macrophages. FASEB J. 2009;23(9):2898-2908.
53. Radtke F, Fasnacht N, Macdonald HR. Notch signaling in the immune system. Immunity. 2010;32(1):14-27.
54. Mongelard F, Bouvet P. Nucleolin: a multiFACeTed protein. Trends Cell Biol. 2007;17(2):80-86. (Pubitemid 46199181)
55. Otake Y, Soundararajan S, Sengupta TK, et al. Overexpression of nucleolin in chronic lymphocytic leukemia cells induces stabilization of bcl2 mRNA. Blood. 2007;109(7):3069-3075. (Pubitemid 46482108)
56. Singh K, Laughlin J, Kosinski PA, Covey LR. Nucleolin is a second component of the CD154 mRNA stability complex that regulates mRNA turnover in activated T cells. J Immunol. 2004;173(2):976-985. (Pubitemid 38924271)
57. Chen CY, Gherzi R, Andersen JS, et al. Nucleolin and YB-1 are required for JNK-mediated interleukin-2 mRNA stabilization during T-cell activation. Genes Dev. 2000;14(10):1236-1248. (Pubitemid 30327504)
58. Barboule N, Truchet I, Valette A. Localization of phosphorylated forms of Bcl-2 in mitosis: co-localization with Ki-67 and nucleolin in nuclear structures and on mitotic chromosomes. Cell Cycle. 2005;4(4):590-596. (Pubitemid 41359788)
59. Grinstein E, Du Y, Santourlidis S, Christ J, Uhrberg M, Wernet P. Nucleolin regulates gene expression in CD34-positive hematopoietic cells. J Biol Chem. 2007;282(17):12439-12449. (Pubitemid 47100621)
60. Grinstein E, Mahotka C, Borkhardt A. Rb and nucleolin antagonize in controlling human CD34 gene expression. Cell Signal. 2011;23(8):1358-1365.
61. González V, Guo K, Hurley L, Sun D. Identification and characterization of nucleolin as a c-myc G-quadruplex-binding protein. J Biol Chem. 2009;284(35):23622-23635.
62. Watson JD, Oster SK, Shago M, Khosravi F, Penn LZ. Identifying genes regulated in a Myc-dependent manner. J Biol Chem. 2002;277(40):36921-36930.
63. Takagi M, Absalon MJ, McLure KG, Kastan MB. Regulation of p53 translation and induction after DNA damage by ribosomal protein L26 and nucleolin. Cell. 2005;123(1):49-63. (Pubitemid 41414528)
64. Ugrinova I, Monier K, Ivaldi C, et al. Inactivation of nucleolin leads to nucleolar disruption, cell cycle arrest and defects in centrosome duplication. BMC Mol Biol. 2007;8:66.
65. Saxena A, Rorie CJ, Dimitrova D, Daniely Y, Borowiec JA. Nucleolin inhibits Hdm2 by multiple pathways leading to p53 stabilization. Oncogene. 2006;25(55):7274-7288. (Pubitemid 44809093)
66. Hovanessian AG, Soundaramourty C, El Khoury D, Nondier I, Svab J, Krust B. Surface expressed nucleolin is constantly induced in tumor cells to mediate calcium-dependent ligand internalization. PLoS One. 2010;5(12):e15787.
67. Inder KL, Lau C, Loo D, et al. Nucleophosmin and nucleolin regulate K-Ras plasma membrane interactions and MAPK signal transduction. J Biol Chem. 2009;284(41):28410-28419.
68. Barel M, Le Romancer M, Frade R. Activation of the EBV/C3d receptor (CR2, CD21) on human B lymphocyte surface triggers tyrosine phosphorylation of the 95-kDa nucleolin and its interaction with phosphatidylinositol 3 kinase. J Immunol. 2001;166(5):3167-3173. (Pubitemid 33117314)
69. Shiohama A, Sasaki T, Noda S, Minoshima S, Shimizu N. Nucleolar localization of DGCR8 and identification of eleven DGCR8-associated proteins. Exp Cell Res. 2007;313(20):4196-4207. (Pubitemid 350087044)
70. Gattoni-Celli S, Buckner CL, Lazarchick J, Stuart RK, Fernandes DJ. Overexpression of nucleolin in engrafted acute myelogenous leukemia cells. Am J Hematol. 2009;84(8):535-538.
71. Yeoh EJ, Ross ME, Shurtleff SA, et al. Classification, subtype discovery, and prediction of outcome in pediatric acute lymphoblastic leukemia by gene expression profiling. Cancer Cell. 2002;1(2):133-143. (Pubitemid 41039160)
72. Hu J, Lin M, Liu T, Li J, Chen B, Chen Y. DIGE-based proteomic analysis identifies nucleophosmin/B23 and nucleolin C23 as over-expressed proteins in relapsed/refractory acute leukemia. Leuk Res. 2011;35(8):1087-1092.
73. Liang J, Lei T, Song Y, Yanes N, Qi Y, Fu M. RNA-destabilizing factor tristetraprolin negatively regulates NF-kappaB signaling. J Biol Chem. 2009;284(43):29383-29390.
74. Schichl YM, Resch U, Hofer-Warbinek R, de Martin R. Tristetraprolin impairs NF-kappaB/p65 nuclear translocation. J Biol Chem. 2009;284(43):29571- 29581.
75. Baou M, Jewell A, Muthurania A, et al. Involvement of Tis11b, an AU-rich binding protein, in induction of apoptosis by rituximab in B cell chronic lymphocytic leukemia cells. Leukemia. 2009;23(5):986-989.
76. Doody G, Care M, Burgoyne N, et al. An extended set of PRDM1/BLIMP1 target genes links binding motif type to dynamic repression. Nucleic Acids Res. 2010;38(16):5336-5350.
77. Vignudelli T, Selmi T, Martello A, et al. ZFP36L1 negatively regulates erythroid differentiation of CD34+ hematopoietic stem cells by interfering with the Stat5b pathway. Mol Biol Cell. 2010;21(19):3340-3351.
78. Kaplan IM, Morisot S, Heiser D, Cheng WC, Kim MJ, Civin CI. Deletion of tristetraprolin caused spontaneous reactive granulopoiesis by a non-cell-autonomous mechanism without disturbing long-term hematopoietic stem cell quiescence. J Immunol. 2011;186(5):2826-2834.
79. Frasca D, Landin A, Alvarez J, Blackshear P, Riley R, Blomberg B. Tristetraprolin, a negative regulator of mRNA stability, is increased in old B cells and is involved in the degradation of E47 mRNA. J Immunol. 2007;179(2):918-927.
80. Stumpo DJ, Broxmeyer HE, Ward T, et al. Targeted disruption of Zfp36l2, encoding a CCCH tandem zinc finger RNA-binding protein, results in defective hematopoiesis. Blood. 2009;114(12):2401-2410.
81. Hodson DJ, Janas ML, Galloway A, et al. Deletion of the RNA-binding proteins ZFP36L1 and ZFP36L2 leads to perturbed thymic development and T lymphoblastic leukemia. Nat Immunol. 2010;11(8):717-724.
82. Galloway A, Hodson D, Janas M, et al. The RNA binding proteins Tis11B and Tis11D are essential for B lymphocyte development. Immunology. 2010;131(suppl 1);79-80.
83. Brennan SE, Kuwano Y, Alkharouf N, Blackshear PJ, Gorospe M, Wilson GM. The mRNA-destabilizing protein tristetraprolin is suppressed in many cancers, altering tumorigenic phenotypes and patient prognosis. Cancer Res. 2009;69(12):5168-5176.
84. Twizere J, Kruys V, Lefèbvre L, et al. Interaction of retroviral Tax oncoproteins with tristetraprolin and regulation of tumor necrosis factor-alpha expression. J Natl Cancer Inst. 2003;95(24):1846-1859. (Pubitemid 38054685)
85. Villanueva R, Iglesias AH, Camelo S, Sanin LC, Gray SG, Dangond F. Histone deacetylase 3 represses HTLV-1 tax transcription. Oncol Rep. 2006;16(3):581-585.
86. Tsukasaki K, Tanosaki S, DeVos S, et al. Identifying progression- associated genes in adult T-cell leukemia/lymphoma by using oligonucleotide microarrays. Int J Cancer. 2004;109(6):875-881. (Pubitemid 38500744)
87. Packham G. The role of NF-kappaB in lymphoid malignancies. Br J Haematol. 2008;143(1):3-15.
88. Jing Q, Huang S, Guth S, et al. Involvement of microRNA in AU-rich element-mediated mRNA instability. Cell. 2005;120(5):623-634. (Pubitemid 40343075)
89. Klein U, Lia M, Crespo M, et al. The DLEU2/miR-15a/16-1 cluster controls B cell proliferation and its deletion leads to chronic lymphocytic leukemia. Cancer Cell. 2010;17(1):28-40.
90. Pospisilova H, Baens M, Michaux L, et al. Interstitial del(14)(q) involving IGH: a novel recurrent aberration in B-NHL. Leukemia. 2007;21(9):2079-2083. (Pubitemid 47299996)
91. Basso K, Saito M, Sumazin P, et al. Integrated biochemical and computational approach identifies BCL6 direct target genes controlling multiple pathways in normal germinal center B cells. Blood. 2010;115(5):975-984.
92. Ci W, Polo JM, Cerchietti L, et al. The BCL6 transcriptional program features repression of multiple oncogenes in primary B cells and is deregulated in DLBCL. Blood. 2009;113(22):5536-5548.
93. Zheng C, Li L, Haak M, et al. Gene expression profiling of CD34+ cells identifies a molecular signature of chronic myeloid leukemia blast crisis. Leukemia. 2006;20(6):1028-1034. (Pubitemid 43797293)
94. Hoelbl A, Schuster C, Kovacic B, et al. Stat5 is indispensable for the maintenance of bcr/abl-positive leukaemia. EMBO Mol Med. 2010;2(3):98-110.
95. Shimada H, Ichikawa H, Nakamura S, et al. Analysis of genes under the downstream control of the t(8;21) fusion protein AML1-MTG8: overexpression of the TIS11b (ERF-1, cMG1) gene induces myeloid cell proliferation in response to G-CSF. Blood. 2000;96(2):655-663. (Pubitemid 30463388)
96. Huang Q, Wu Y, Snyder DS, et al. Clinical and pathologic analysis of 16 cases of relapsed chronic myeloid leukemia after stem cell transplantation. Am J Clin Pathol. 2007;128(4):565-570. (Pubitemid 47584433)
97. Chapman MA, Lawrence MS, Keats JJ, et al. Initial genome sequencing and analysis of multiple myeloma. Nature. 2011;471(7339):467-472.
98. Iwanaga E, Nanri T, Mitsuya H, Asou N. Mutation in the RNA binding protein TIS11D/ZFP36L2 is associated with the pathogenesis of acute leukemia. Int J Oncol. 2011;38(1):25-31.
99. Lal A, Mazan-Mamczarz K, Kawai T, Yang X, Martindale J, Gorospe M. Concurrent versus individual binding of HuR and AUF1 to common labile target mRNAs. EMBO J. 2004;23(15):3092-3102. (Pubitemid 39093603)
100. Kedar VP, Darby MK, Williams JG, Blackshear PJ. Phosphorylation of human tristetraprolin in response to its interaction with the Cbl interacting protein CIN85. PLoS One. 2010;5(3):e9588.
101. Brooks S, Connolly J, Rigby W. The role of mRNA turnover in the regulation of tristetraprolin expression: evidence for an extracellular signal-regulated kinase-specific, AU-rich element-dependent, autoregulatory pathway. J Immunol. 2004;172(12):7263-7271. (Pubitemid 38747585)
102. Pullmann R, Kim H, Abdelmohsen K, et al. Analysis of turnover and translation regulatory RNA-binding protein expression through binding to cognate mRNAs. Mol Cell Biol. 2007;27(18):6265-6278. (Pubitemid 47435735)
103. Planel S, Salomon A, Jalinot P, Feige JJ, Cherradi N. A novel concept in antiangiogenic and antitumoral therapy: multitarget destabilization of short-lived mRNAs by the zinc finger protein ZFP36L1. Oncogene. 2010;29(45):5989-6003.